Mestinon (pyridostigmine bromide) is primarily used to treat myasthenia gravis, an autoimmune condition that causes muscle weakness. It works by preventing the breakdown of a chemical messenger called acetylcholine at the junction between nerves and muscles, which helps muscles contract more effectively. Beyond myasthenia gravis, it’s also prescribed off-label for conditions involving the autonomic nervous system, particularly postural orthostatic tachycardia syndrome (POTS).
How Mestinon Works
In healthy muscles, nerve endings release acetylcholine to signal a muscle to contract. An enzyme then quickly clears that acetylcholine away so the signal doesn’t keep firing. In myasthenia gravis, the immune system attacks the receptors that receive those signals, so fewer of them work. Mestinon blocks the enzyme that clears acetylcholine, allowing it to linger longer and have more chances to bind to the remaining receptors. The result is stronger, more sustained muscle contractions.
This same mechanism is useful beyond muscle weakness. Because acetylcholine also plays a role in regulating heart rate, blood pressure, and other involuntary body functions, boosting its levels can help stabilize parts of the autonomic nervous system that aren’t working properly.
Myasthenia Gravis
Myasthenia gravis is the condition most closely associated with Mestinon. People with this disease experience weakness that worsens with activity and improves with rest, often affecting the eyes, face, throat, and limbs. Mestinon doesn’t cure the disease or address the underlying immune attack, but it reliably improves muscle strength for several hours per dose, making everyday tasks like chewing, swallowing, and walking easier.
Effects typically begin 30 to 60 minutes after taking a dose and last three to four hours during the day. Doses taken at bedtime often provide a longer effect of around six hours, which can help with morning weakness. Most people take multiple doses throughout the day, timed so that peak strength lines up with meals, work, or other activities that demand the most from their muscles.
Postural Orthostatic Tachycardia Syndrome
POTS causes an excessive rise in heart rate when you stand up, often accompanied by lightheadedness, fatigue, palpitations, and sometimes fainting. Mestinon is one of several medications used off-label to manage it. A study of 203 POTS patients treated with pyridostigmine found that 51% of those who tolerated the drug experienced meaningful symptom improvement. The symptoms that responded best were palpitations (60% improvement), presyncope (60%), fatigue (55%), and fainting episodes (48%).
Patients in that study started at a low dose of 30 mg twice daily, with gradual increases over several weeks up to 60 mg three times daily or 90 mg three times daily if needed. Standing heart rate dropped from an average of 94 beats per minute to 82 after treatment, a clinically significant change. Not everyone responds, and about 17% of patients in the study couldn’t tolerate the medication at all, mostly due to gastrointestinal side effects.
Orthostatic Hypotension
Orthostatic hypotension, a condition where blood pressure drops sharply upon standing, has also been treated with Mestinon. One randomized trial found that a single 60 mg dose reduced the blood pressure drop from 34 mmHg with placebo to about 28 mmHg. A separate study found significant improvement in blood pressure drops at three months of treatment.
The evidence here is mixed, though. Two other randomized trials found no significant benefit in patients with severe autonomic failure, suggesting that Mestinon may work better for milder forms of the condition. When the nervous system damage controlling blood vessels is too extensive, boosting acetylcholine levels may not be enough to compensate.
Military Nerve Agent Pretreatment
Mestinon has a separate, lesser-known FDA approval as a pretreatment against soman nerve agent poisoning in adults. In this context, it’s taken before potential exposure alongside protective gear and emergency antidotes. It is not approved for protection against other nerve agents like sarin or tabun. This use is limited to military settings and has no relevance to civilian medical care.
Available Forms and Dosing
Mestinon comes in three forms: a 60 mg immediate-release tablet, a raspberry-flavored liquid solution (60 mg per teaspoon), and a 180 mg sustained-release tablet called Mestinon Timespan. The immediate-release version is the workhorse for most patients, taken multiple times throughout the day. For myasthenia gravis, the average daily dose is around 600 mg (ten tablets), though mild cases may need as few as one to six tablets and severe cases may require up to 25.
The Timespan tablet releases medication slowly and lasts about two and a half times longer than a standard tablet. One to three Timespan tablets taken once or twice daily can reduce the number of doses needed, with at least six hours between each. Many people use both forms together: Timespan for baseline coverage and immediate-release tablets for extra strength during demanding parts of the day.
Common Side Effects
Because Mestinon increases acetylcholine throughout the body, not just at the muscles you want to strengthen, it activates other systems too. The most common side effects involve the gut: abdominal cramping, diarrhea, and nausea. About 19% of POTS patients in one study reported gastrointestinal problems severe enough to be notable. Increased salivation, sweating, and increased mucus in the airways can also occur.
Muscle twitching and cramping are another set of side effects, caused by overstimulation at the nerve-muscle junction. These tend to be less bothersome than the digestive symptoms for most people.
Cholinergic Crisis
Taking too much Mestinon can paradoxically cause weakness rather than improve it, a condition called cholinergic crisis. This is dangerous because it looks nearly identical to a worsening of myasthenia gravis, and the two require opposite treatments. In practice, cholinergic crisis is rare and typically only occurs at doses well above 120 mg every three hours or a total daily dose exceeding 960 mg. If weakness increases, the more likely explanation is that the underlying condition is getting worse rather than that the medication dose is too high.
Important Precautions
Intravenous pyridostigmine can trigger uterine contractions, so it’s not recommended during pregnancy. Medications with anticholinergic properties, which work in the opposite direction of Mestinon, can cancel out its effects or worsen myasthenia gravis symptoms. Certain heart rhythm medications fall into this category. If you’re taking Mestinon and a new medication is being considered, the interaction between cholinergic and anticholinergic effects is worth flagging to your prescriber.